Nycomed plans to increase diagnostics development
This article was originally published in Clinica
Executive Summary
Norwegian company Nycomed will increase product development in generics and in vitro diagnostics while scaling down its exploratory R&D in the pharmaceutical area. Trond Jacobsen, executive vice-president for product sourcing, said at a UBS investment conference in London at the end of March, that Nycomed is reviewing its entire R&D pipeline and will present the results at the beginning of April.